ByteDance spin-off Anew Labs raises $290M at $1.5B valuation

Anew Labs, the Shanghai-based AI drug discovery startup that began as a unit of ByteDance, has raised $290 million at a $1.5 billion valuation, according to an informed source. The round, which closed this week, is part of a broader fundraising surge for AI drug developers in China, as investors rush to back domestic challengers to Western firms like Anthropic and Isomorphic Labs. The deal is the latest sign that Chinese investors are pouring hundreds of millions into startups that apply machine learning to drug discovery, with Anew Labs among several firms to announce major rounds this week, though the source did not name the others. The company's backers include prominent venture capital firms, though specific names were not disclosed in the report.

Anew Labs was formerly a unit of ByteDance, the Chinese tech giant best known for TikTok. The spin-off allows the startup to operate independently, though it retains the technical pedigree of its parent. For ByteDance, the move frees the company from the capital-intensive and highly regulated drug development business while still benefiting from any future upside through its stake. This structure mirrors a broader trend of tech conglomerates spinning off biotech ventures to unlock value and focus on core operations.

AI drug discovery uses algorithms to analyze biological data, predict molecular interactions, and identify promising drug candidates far faster than traditional methods. The approach has attracted billions in funding globally, with companies like Anthropic and Isomorphic Labs - Alphabet's DeepMind spin-off - leading the charge in the West. In China, a new generation of startups is now vying for a share of that market, backed by local venture capital and government support for biotech innovation. The fundraising boom reflects a broader shift in how drugs are developed, compressing the timeline from target identification to clinical trials and potentially disrupting the traditional pharma model, where development cycles often stretch a decade or more.

For established drugmakers, the rise of these startups presents both a threat and an opportunity. They could become acquisition targets or licensing partners, or they could outcompete incumbents in specific therapeutic areas. China's regulatory environment has become more supportive of AI-driven drug development in recent years, with the National Medical Products Administration streamlining approval pathways for innovative therapies. At the same time, the country's vast patient pool and growing healthcare spending make it an attractive market for AI-discovered drugs. However, challenges remain, including data privacy concerns and the need for clinical validation.

For executives in pharma, biotech, and venture capital, the Anew Labs round is a signal to pay attention to China's AI drug ecosystem. The valuation of $1.5 billion for a company with no approved products underscores the premium investors are placing on AI capabilities. As more capital flows into this space, expect to see increased competition for talent, partnerships, and intellectual property. Companies that ignore this trend risk being left behind as AI becomes a standard tool in drug discovery. The round also highlights the growing convergence of tech and biotech, where data-driven approaches are reshaping how medicines are conceived, tested, and brought to market.